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Abstract
Background An increasing number of model-based studies
that evaluate the cost effectiveness of treatments for
depression are being published. These studies have differ-
ent characteristics and use different simulation methods.
Objective We aimed to systematically review model-based
studies evaluating the cost effectiveness of treatments for
depression and examine which modelling technique is most
appropriate for simulating the natural course of depression.
Methods The literature search was conducted in the data-
bases PubMed, EMBASE and PsycInfo between 1 January
2002 and 1 October 2016. Studies were eligible if they used
a health economic model with quality-adjusted life-years or
disability-adjusted life-years as an outcome measure. Data
related to various methodological characteristics were
extracted from the included studies. The available mod-
elling techniques were evaluated based on 11 predefined
criteria.
Results This methodological review included 41 model-
based studies, of which 21 used decision trees (DTs), 15
used cohort-based state-transition Markov models
(CMMs), two used individual-based state-transition models
(ISMs), and three used discrete-event simulation (DES)
models. Just over half of the studies (54%) evaluated
antidepressants compared with a control condition. The
data sources, time horizons, cycle lengths, perspectives
adopted and number of health states/events all varied
widely between the included studies. DTs scored positively
in four of the 11 criteria, CMMs in five, ISMs in six, and
DES models in seven.
Conclusion There were substantial methodological differ-
ences between the studies. Since the individual history of
each patient is important for the prognosis of depression,
DES and ISM simulation methods may be more appro-
priate than the others for a pragmatic representation of the
course of depression. However, direct comparisons
between the available modelling techniques are necessary
to yield firm conclusions.
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Key Points for Decision Makers
Substantial methodological differences exist
between model-based studies evaluating depression
treatments.
Simpler models, such as decision trees and cohort-
based Markov models, were more frequently used.
Microsimulation models, such as individual-based
state-transition models and discrete-event simulation
models, incorporate patient heterogeneity and
history, which is important when modelling
depression.
1 Introduction
Depression is associated with an enormous burden for
patients, healthcare systems and society as a whole. The
World Health Organization has estimated that depression
will rank first among the most debilitating conditions in
terms of disability-adjusted life-years (DALYs) by the year
2030 [1]. Individuals with depression experience impair-
ments in many aspects of their life, resulting in signifi-
cantly lower quality of life (QoL) than the general
population [2–4]. Additionally, depression leads to an
immense economic burden [5]. In the USA, the total costs
of depression were estimated to be $US173 billion in 2005
and $US202 billion in 2010 [6], whereas in Europe the total
expenses related to depression were estimated to be
approximately €92 billion in 2010 [7, 8].
Depression is very common, with a lifetime prevalence
between 10 and 15% [9]. Patients with depression consti-
tute a rather heterogeneous group [10], which may also
affect the effectiveness and cost effectiveness of treatments
[11, 12]. Evidence exists that various evidence-based
treatments are similarly effective against depression, but
whether specific treatments can be more beneficial for
patients with specific characteristics remains unclear [13].
More than 50% of the patients seeking treatment for
depression experience recurrent depressive episodes, the
mean duration of which is 16 weeks [14]. Previous epi-
sodes are significantly related to the probability of recur-
rence, with the risk for a new depressive episode increasing
by 16% for each successive recurrence [15]. Furthermore,
the probability of recurrence decreases as the period that
the patient is in recovery increases. Depression often is
comorbid with other mental disorders, such as anxiety or
substance abuse, or physical disorders such as diabetes
[14, 16]. Therefore, the personal history of each individual
is important for the prognosis of depression.
Economic evaluations are frequently used to inform deci-
sions about the allocation of scarce resources in healthcare
[17, 18]. They can be conducted either alongside randomized
controlled trials (RCTs) or using economic modelling tech-
niques. The current paper focuses on modelling techniques.
The three dominant modelling methods used in model-based
studies for commonmental health disorders are decision trees
(DTs), state-transition Markov models (MMs), and discrete-
event simulation (DES) models [19–21]. These modelling
techniques have different strengths and limitations, and the
choice of one over the other depends on several factors, such
as the complexity of the decision problem, data accessibility
and available expertise [22]. A recent literature review com-
pared MMs and DES for the economic evaluation of health-
care technologies such as breast cancer treatments without
focusing specifically on depression [20]. The authors con-
cluded that DES showed a few profound advantages over
MMsbut that thefinal choicedepends on the researchquestion
being addressed [20]. So far, the most appropriate modelling
method to use when simulating the course of depression and
the impact of treatment on this course remains unclear.
Economic modelling in the research field of depression
has received increased attention in recent years. Afzali et al.
[21] conducted a systematic literature search up to Septem-
ber 2010 reviewing model-based cost-effectiveness studies
of depression treatments. The authors focused on the char-
acteristics of the model-based studies and evaluated how
these characteristics influenced the results. They identified
wide variation in the methodological aspects of the included
studies and concluded that these differences potentially
influence the accuracy of the cost-effectiveness estimations
[21]. Another systematic review examined model-based
studies of pharmacotherapy for major depression, published
up to May 2010, and reached similar conclusions [23].
Many additional modelling studies have been published
since 2010, and we considered it opportune to update the
review by Afzali et al. [21] because periodic updating of
evidence is important to avoid stakeholders using outdated
evidence to inform decisions or address new problems.
Therefore, the first objective of the current study was to
investigate the methodological characteristics of model-
based studies examining the cost effectiveness of treat-
ments for depression. Second, we aimed to examine which
of the modelling methods was more appropriate for simu-
lating the course of depression.
2 Methods
2.1 Literature Search
To answer the first research question, we updated the
systematic review by Afzali et al. [21]. The first author
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(SK) searched the databases PubMed, EMBASE and Psy-
cInfo for eligible studies published between 1 January 2002
and 1 October 2016. This timeframe overlaps with that
examined by Afzali et al. [21] (2002–2010) because we
developed our own search strategy and wanted to ensure
the same search criteria were applied for all years consid-
ered. We used search terms referring to model-based eco-
nomic evaluations and depression treatments (see
Appendix 1 in the Electronic Supplementary Material
[ESM] for the full search string). We searched for pub-
lished studies written in English. No protocol was pub-
lished for this review. We input all entries from the
database searches into a reference manager and removed
the duplicates. The titles and abstracts were screened for
eligibility, and the full texts were then examined.
2.2 Inclusion Criteria
Studies were included when they fulfilled the following
criteria: (1) used a health economic model, (2) examined
the cost effectiveness of treatments for adults with
depression and (3) estimated quality-adjusted life-years
(QALYs) or DALYs. Health economic models were
defined as a mathematical representation of reality that can
be used to estimate the cost effectiveness of health tech-
nologies for depression [21]. Depression was defined as a
diagnosis of major depressive disorder based on a struc-
tured clinical interview or a score on a standardized self-
report measure of depressive symptom severity that indi-
cates the presence of clinically relevant depression. We
included studies using QALYs or DALYs, which is similar
to the inclusion criteria used by Afzali et al. [21]. This
approach was adopted to increase the homogeneity of the
reviewed studies. At the same time, the amelioration of the
QoL of patients with depression is one of the main goals of
treatment for depression and thus a relevant outcome in the
context of this study [24]. No restrictions were applied on
treatments evaluated (i.e. pharmacotherapy, psychotherapy,
combination treatments, other) or the control groups.
Studies on the prevention of depression were excluded.
Any ambiguity around whether a study should be included
was discussed with another author (JEB) until consensus
was reached.
2.3 Data Extraction and Analysis
Data were extracted on the modelling technique used (e.g.
DTs, cohort-based state-transition MMs [CMMs]), the
structure of the model (i.e. what health states/events were
used to represent the natural course of depression), data
sources (e.g. meta-analysis, RCTs), time horizon and cycle
length, treatment comparisons (i.e. which intervention and
control groups were compared) and sensitivity analyses and
economic perspective (e.g. societal or healthcare system
perspective). Data extraction was performed by the first
author (SK) using a data form developed based on the
review by Afzali et al. [21]. When data were missing or
unclear, we emailed the first author of the paper to request
additional information. The extracted data were presented
using descriptive statistics such as means and percentages
whenever possible.
2.4 Comparison of Modelling Techniques
We grouped the modelling methods into four classes:
DTs, CMMs, individual-based state-transition models
(ISMs), and DES models (see the Results section for a
description of each modelling method). We used 11
predefined criteria to evaluate the appropriateness of
each modelling technique for simulating the course of
depression. These criteria were introduced by Brennan
et al. [25] to provide guidance on key requirements of
modelling methods and have been previously used in
schizophrenia [26]. We aimed to extract information on
the included studies for each criterion (e.g. how much
building time the model required, were data available as
required to populate the model, did the authors comment
on the simulation time required, etc.). If information was
not available in the included studies for a specific cri-
terion, we searched the literature to identify data on the
performance of each model on this criterion. The criteria
were building time, data collection, experience, simula-
tion time, clinical representation, patient heterogeneity,
timing of events, memory, patient interaction, interaction
due to covariates and variability (see Table 1 for a short
definition of each criterion). We discussed the perfor-




Figure 1 describes the results of the literature search. The
search yielded 7757 titles; 6570 references remained after
duplicates were removed. After screening the titles and
abstracts, we retrieved the full texts of 113 studies and
excluded 72 (16 no depression, 35 no model-based studies,
18 no QALYs or DALYs, two prevention of depression,
and one no adults). We included 41 studies compared with
the 14 studies included by Afzali et al. [21] (Fig. 1).
The included studies used different health economic
modelling techniques (Table 2): 21 (51%) studies used
DTs, 15 (37%) used CMMs, two (5%) used ISMs and three
(7%) used DES modelling techniques.
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3.2 Characteristics of Model-Based Studies
for Depression
3.2.1 Time Horizon and Cycle Length
In the studies using DTs, the time horizon varied consid-
erably between 6 weeks and 27 months. Likewise, in those
using CMMs, the time horizon varied between 4 months
and lifetime and the cycle length ranged from 1 week to
6 months (Table 2). In the two studies using ISMs, the time
horizon was 3 and 5 years and the cycle length 2 months
and 1 month, respectively. Finally, one of the three studies
that used DES models had a time horizon of 5 years [27]
and the other two used a lifetime time horizon (Table 2)
[28, 29].
3.2.2 Perspective
In total, 12 (29%) studies adopted the societal perspective,
which included all relevant direct and indirect healthcare
costs and lost productivity costs, and 21 studies (51%) used
the healthcare perspective, which included only healthcare
costs. Six studies (16%) used the managed care organiza-
tion perspective, which included the costs from the per-
spective of the organization providing the healthcare
(Table 2), and, finally, one study (2%) used the employer’s
perspective and one study (2%) used the payer’s
perspective.
3.2.3 Treatment and Comparator
Just over half of the studies (22 [54%]) evaluated the cost
effectiveness of pharmacological treatments for depres-
sion. Seven (17%) examined combined treatments, mostly
a combination of antidepressants and psychological
treatments. Four (10%) investigated psychological treat-
ments, and two (5%) investigated antidepressant treatment
in combination with genotyping. Two studies (5%)
examined electroconvulsive therapy (ECT) and two (5%)
studied repetitive transcranial magnetic stimulation
(rTMS). Finally, two studies (5%) examined the cost
effectiveness of positive mental training and St John’s
Wort (Table 2).
Table 2 also presents the comparator in the included
models: 23 (56%) studies used antidepressant medication
as a comparator; seven (17%) used more than one com-
parator, including psychological treatments, no treatment,
and combination treatments; and five (12%) compared the
treatment under study with treatment as usual. Other
comparators were computerized cognitive behavioural
therapy, placebo pills, rTMS, and ECT (Table 2).
Table 1 Description of 11 criteria used to evaluate the appropriateness of each modelling technique to simulate the course of depression.
Adapted from Heeg et al. [26]
Criterion Description
Building time Time required to develop and program the model
Data collection Availability and time required to collect data to populate the model
Experience Number of published studies using each modelling method in healthcare literature
Simulation time Computational time needed to generate results
Clinical representation Ability to simulate the problem pragmatically by including all the relevant aspects
Patient heterogeneity Ability to deal with patients having different clinical and demographic characteristics
Timing of events Ability to allow for recurrent events to occur
Memory Ability to track each patient and allow the personal history to influence future events
Patient interaction Ability to include interaction between patients
Interaction due to covariates Ability to include covariates that interact or influence future events






113 Full-text papers retrieved
41 Studies analyzed
1187 Duplicates
6457 Studies excluded by title 
and abstract 
72 Studies excluded: 
16 No depression
35 No model-based study
18 No QALYs or DALYs
2 Prevention of depression
1 No adults
Fig. 1 Flowchart describing the search strategy. DALY disability-
adjusted life-year, QALY quality-adjusted life-year
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3.2.4 Structure of the Models
The structure of the models varied considerably between
the studies. The most frequently used health states or
events were response, remission, relapse and death
(Table 2). Three studies (7%) used different states for
different levels of depression severity (i.e. minimal, mild,
moderate and severe depressive symptoms), and 13 studies
(32%) included one or more of the health states discon-
tinuation, second-line options and adverse events related to
antidepressant medication.
3.2.5 Data Sources
The data sources that can be used as inputs for a health
economic model have different strengths and limitations,
but they must all be transparent and well documented
[30, 31]. The included studies used various data sources to
populate the model (Table 3). These sources included but
were not limited to published RCTs, meta-analyses of
RCTs, observational studies and expert opinions.
A total of 27 studies (66%) used meta-analysis to derive
clinical inputs. Since meta-analyses are based on a system-
atic literature search using predefined inclusion criteria, the
possibility of selection bias is decreased. Expert opinion,
which is considered an unreliable data source because of its
subjective nature, was used in 15 studies (37%). Most of the
studies used published data sources to estimate utility
weights, such as RCTs or observational studies. Two studies
(5%) used a depressive symptom severity measure to cal-
culate utility weights, and two other studies (5%) converted
depression-free days to utility weights (Table 3).
3.2.6 Sensitivity Analysis
All included studies carried out sensitivity analyses to
examine the uncertainty around the study parameters
(Table 3). The two basic purposes of sensitivity analysis are
to investigate the robustness of a chosen course of action and
to accumulate additional information surrounding a specific
decision [32]. Of the included studies, 29 (70%) performed a
univariate sensitivity analysis, six (15%) carried out a
multivariate sensitivity analysis and six (15%) conducted
both univariate and multivariate analyses (Table 3). The
sensitivity analysis was probabilistic in 31 (77%) of the
studies, deterministic in three (7%) and both probabilistic
and deterministic in seven (17%).
3.3 Comparison of Modelling Techniques
We used 11 criteria to evaluate the appropriateness of the
four modelling methods (DTs, CMMs, ISMs and DES)
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Table 3 Data sources and sensitivity analysis
Study Primary source of data Sensitivity analysis
Clinical inputs Cost Utility
Armstrong
et al. [68]
















































































Meta-analysis of RCTs Published national data,
published literature, RCT









Published clinical trial data Univariate and multivariate




Observational studies Published national data,
expert opinion








Observational studies National sources, published
literature






UK NHS Using a published approach to







Meta-analysis of RCTs National sources, expert
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Meta-analysis Published literature, expert
opinion, RCT






























Published literature Univariate and multivariate
sensitivity analysis, PSA
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evaluate the models on the predefined criteria. An overview
of this evaluation is presented in Table 4. A description of
the criteria applied to each modelling method, with a
specific focus on the importance of these criteria when
modelling the cost effectiveness of depression treatments,
follows.
3.3.1 Decision Trees
DTs scored positively in four of the 11 criteria (Table 4).
DTs are used to represent relatively simple decision
problems and are mainly appropriate for modelling inter-
ventions over short time horizons [22]. This is reflected in
Table 3 continued
Study Primary source of data Sensitivity analysis











Meta-analysis of RCTs Published literature,
national sources




















































































RCTs, meta-analysis Published database,
observational study



















Meta-analysis of RCTs National sources and claims
database
Using a published approach to



















Published literature using SG Univariate sensitivity analysis,
PSA
BDI Beck Depression Inventory, DALYs disability-adjusted life-years, DFD depression-free days, DSA deterministic sensitivity analysis, EQ-5D
EuroQol 5-Dimensions, NHS national healthcare service, PSA probabilistic sensitivity analysis, RCT randomized controlled trial, SG standard
gamble
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our finding that the average time horizon in the studies
using DTs was 10 months. They are generally simple to
build and analyse. A DT typically includes a small number
of health states and has low data requirements. This was
also reflected in the studies included in this review, as the
majority used between two and four health states (Table 2).
This may pose a threat to the clinical representation of
depression in these models, since depression typically has
an intermittent course. DT is probably the most popular
modelling technique in simulating depression (n = 21
[51%]) because of the low requirements for time to
develop, data inputs and expertise. For example, most of
the included studies used a dedicated software such as
TreeAge Pro [33] or other statistical software such as
Microsoft Excel and WinBUGS [34] to develop the DTs.
A DT typically focuses on the average patient. For
instance, the included studies using DTs did not differen-
tiate between patients with comorbidity or different age
groups while simulating the course of depression. Fur-
thermore, DT does not track the individual history of a
patient, and passing of time is not included in the model.
This means that DTs do not include variability in patient
characteristics over time (e.g. increase the probability of a
future recurrence after each additional depressive episode).
This is a disadvantage of DTs, because depression is a
chronic disorder for many patients, and it is important to
model long-term outcomes that are influenced by previous
events.
The time horizon used in the included DT studies varied
between 6 weeks and 27 months. This may be a short
period for a recurrent disorder such as depression, for
which the average episode is 16 weeks and more than half
of patients experience more than one episode [14]. How-
ever, a longer time horizon would substantially increase the
complexity of the model, making it difficult to handle. In
addition, patient heterogeneity and interactions between
variables are typically not included in DTs, but this can be
implemented by running separate models for each sub-
group or adding more health states to the model, respec-
tively. However, this may also lead to an exponential
increase in model size. These issues may decrease the face
validity of DT models for depression. Only three of the
reviewed studies that included DTs explicitly reported
validation methods. Two used expert panels to validate the
data sources and one used individual panellists to verify the
model estimates [35–37].
3.3.2 Cohort-Based State-Transition Markov Model
The CMM scored positively in five of the 11 criteria
(Table 4). The number of studies using CMMs (15 [37%])
indicated it was the second most popular technique to
model depression. A CMM is most suitable for situations in
which the decision problem can be represented in terms of
health states and the population under study is a closed
cohort [38]. Portions of the cohort simultaneously move
from one health state to the other. The model is ‘memo-
ryless’, a condition known as the ‘Markovian property’,
meaning that future health states depend only on the cur-
rent health state and not on the sequence of previous health
states [38]. Therefore, the included studies using CMM did
not account for patient history since the initiation of the
simulation (e.g. time spent in previous health states). This
is an essential drawback of using a CMM to simulate
depression, because various patient characteristics (e.g.
baseline depression severity, comorbidity, previous epi-
sodes, etc.) play an important role in prognosis and treat-
ment decisions [39–41].
Table 4 Strengths and weaknesses of four modelling techniques for simulating the course of depression





Building time ? ? - -
Data collection ? ? - -
Experience ? ? ? -
Simulation time ? ? - -
Clinical representation - - ? ?
Patient heterogeneity - - ? ?
Time of events - ? ? ?
Memory - - ? ?
Patient interaction - - - ?
Interaction due to covariates - - - ?
Variability - - ? ?
DES discrete-event simulation, ? indicates modelling technique was evaluated positively for this criterion, - indicates modelling technique was
evaluated negatively for this criterion
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Nevertheless, additional health states or ‘tunnel’ states
can be added to model patient history and heterogeneity or
timing of events such as time spent in a depressive episode;
these models are also called semi-Markov models. How-
ever, this may increase the complexity of the model con-
siderably, resulting in a model that is rather difficult for
analysts and researchers to manage and for decision makers
and other stakeholders to interpret [38]. Only three of the
13 included studies used ‘tunnel states’. Thus, most studies
using CMM did not include the timing of events and
patient heterogeneity in the models.
CMM is relatively easy to build, and most of the
included studies used Microsoft Excel and Visual Basic
applications or dedicated software such as TreeAge Pro
[33] to develop the model. An advantage of CMM is that,
similar to DTs, it has relatively low data requirements.
However, and in comparison with DTs, it is easier for
CMM to simulate different courses of disease and thus it
has better clinical representation and face validity. Other
validation methods were reported in four CMM studies,
including validation of the model structure and approach
by a panel of clinicians, verification of the model algorithm
(internal validity), validation of the model’s assumptions
by experts, and comparison of model predictions with
estimates from published literature (external validity)
[42–45].
3.3.3 Individual-Based State-Transition Model
The ISM scored positively in six of the 11 criteria
(Table 4). Two studies employed an ISM that was a state-
transition model such as CMM but was not limited by the
Markovian property [38]. Instead of cohort simulation,
ISM is a microsimulation model that simulates one patient
at a time. The two included studies that used ISM tracked
the individual history of the patients (in terms of increased
risk for a future depressive episode after each new epi-
sode). They also included patient heterogeneity in the
model by providing different transition probabilities based
on patient characteristics, such as sex and age. In other
words, ISM can include timing of events and memory in
the model. However, this may increase the development
and running time of the model considerably. The two
studies used TreeAge Pro [33] to build the model.
The complexity of the model means data requirements
are also higher than with DT and CMM (e.g. separate
transition probabilities must be found for men and women
or patients in different age groups), and this is a consid-
erable issue. Although the volume of meta-analyses, RCTs
and observational studies investigating depression in the
literature is always increasing, there is no consensus on
instruments to monitor the severity of depression and on
the definitions of related health states such as remission and
response. As a result, searching for data to populate the
models can be inefficient and time consuming. Data
availability was also an issue in the included studies; 37%
relied at least partly on expert opinion as a data source for
some clinical or cost parameters.
A further issue related to the use of ISM that also applies
to CMM is the need to define a fixed cycle length [38, 46].
The choice of cycle length depends upon treatment length,
data availability and frequency of clinical events, among
others. Shorter cycle lengths give a better approximation of
the events in real life but increase the computational bur-
den in terms of data requirements and running time [38].
The cycle length should be short enough to incorporate the
impact of important events such as treatment outcomes.
Thus, considering the intermittent course of depression
over time, cycle lengths longer than 3 months may not be
appropriate. The two studies we identified as using ISMs
had cycle lengths of 1 and 2 months.
The authors of these two studies did not provide an
explicit explanation regarding why they chose a
microsimulation approach instead of a CMM. The ability
of studies using ISM to model patient heterogeneity and
memory can potentially improve the face validity of the
model. The authors did not provide further information on
other formal methods they used to validate the models.
3.3.4 Discrete-Event Simulation
DES modelling scored positively in seven of the 11 criteria
(Table 4). It has been used extensively for other healthcare
applications, such as surgical disciplines, but we identified
only three studies of depression (7%). Using DES results in
a microsimulation model in which each patient is simulated
separately, similar to using an ISM. DES models do not use
fixed cycles, instead, a constantly running simulation clock
tracks time [47]. Thus, the model advances from one event
to another and these interim periods (e.g. remission from
depression) can be captured by referring to the simulation
clock [47]. The time at which an event occurs is based on a
survival function that models the time to that specific
event.
Because of this flexible time management, an event can
occur at any time, which is particularly useful when sim-
ulating recurrent disorders such as depression, where most
patients are expected to experience multiple episodes. This
flexibility in time can be approximated in state-transition
models such as CMM and ISM. For instance, one of the
included studies that used CMM had a cycle length of
2 weeks. Nevertheless, using very short cycle lengths may
increase the running time of the state-transition models
considerably.
Although patient interactions such as waiting lists,
which are common in specialized depression care, can also
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be implemented in the model, our literature search did not
find any studies using this capability. The complexity of
the model means the building and running time can be
substantial. The expertise required to build and analyse
DES models may be behind the limited use of this type of
modelling in depression thus far. Nevertheless, dedicated
software for DES models does exist, such as Simul8 [48],
which one of the three studies used. The other two studies
used Microsoft Excel. In addition, data requirements are
higher, posing a concern similar to that discussed for the
ISM. However, DES is expected to represent the course of
depression more naturally than DT or CMM because it is
possible to model the effects of patient characteristics on
the course of depression [49].
The authors of studies using DES models reported that
they did so because of the complexity of the model they
wanted to build and the ability to include patient hetero-
geneity and history [28, 29]. These advantages of DES
modelling can enhance the face validity of the model. One
[29] of the three studies described other methods of vali-
dation, including a workshop developed to validate the
conceptual and mathematical models, testing of the model
code and results by a second analyst, and error checking by
the project team.
4 Discussion
This study aimed to review the methodological character-
istics of model-based studies examining the cost effec-
tiveness of treatments for depression and to evaluate which
of the modelling methods was more appropriate for simu-
lating the course of the disorder. The 41 studies had diverse
methodological aspects and therefore it was difficult to
compare them. Simpler models (i.e. DT and CMM) were
used more frequently. However, microsimulation models
(i.e. ISM and DES) appeared more appropriate when
simulating the course of depression because they can track
the personal history of each individual.
About half of the identified studies investigated antide-
pressants compared with a comparator treatment. However,
practice guidelines recommend both psychological and
pharmacological treatments for depressive disorders
[50–52]. In addition, preliminary evidence from a meta-
analysis showed that cognitive behavioural therapy and
continuation of pharmacotherapy had similar long-term
effects on depression [53]. Therefore, model-based eco-
nomic evaluations of psychological treatments are neces-
sary to examine the cost effectiveness of these
interventions in the long term.
The included studies used various data sources to pop-
ulate the models. Data from RCTs were commonly used to
derive effect estimates. RCTs are methodologically sound
but they sometimes have low external validity because of
strict inclusion criteria [18, 54]. Meta-analysis of RCTs has
increased precision and external validity than a single
clinical trial, but the results may still be subject to publi-
cation bias [54, 55]. Observational studies typically have
larger samples and higher external validity than RCTs [21];
however, the quality of the data is usually lower than in an
RCT because it is difficult to control for confounding bias.
Expert opinion is a controversial choice that may be used
only when no other sources are available [18, 56]. We
found 15 studies (37%) used expert opinion as the data
source for clinical or cost inputs, which may be an indi-
cation of a lack of valid data for some parameters. The
issue of the limited number of papers available in the lit-
erature presenting utility weights for different health states
of depression has been addressed previously [57]. A recent
systematic review and meta-analysis can provide a useful
resource for decision analysts [58]. Overall, researchers
should be cautious when using utility weights from the
literature and ensure the weights they use are applicable to
the specific population and health states they are
evaluating.
The structure of the model must address the decision
problem adequately [59]. The majority of the studies used
relatively simple model structures with only a few health
states, sometimes as few as two, with an average of four.
Since depression is recurrent, with increased risk for sui-
cide, it seems reasonable that the structure of the models
needs to be relatively complex. Some key clinical events
should be remission (ideally defined by a structured clinical
interview) and a measure of symptom improvements (such
as response or reliable change) and deterioration. Deteri-
oration of depressive symptoms is often only partly
included in the models as relapsing to depression after
being in remission. However, it is possible that patients get
worse while undergoing treatment for depression [60].
Moreover, depressive symptom severity is related to dif-
ferent utility weights, with more depressed patients having
more deteriorated QoL [58]. Thus, accounting for severity
of depression would improve the clinical representation of
the models. Nevertheless, only three of the included studies
used different states for different levels of depression
severity. Overall, omitting important health states from the
model structure may lead to overestimation or underesti-
mation of the cost effectiveness of the treatment under
study.
We searched the included papers for information on
model validation. Model validation is crucial since it pro-
vides confidence to decision makers that the model accu-
rately predicts the outcomes of interest [61]. We identified
minimal information on validation methods. Although the
body of literature on the importance of rigorous validation
of statistical modelling is substantial [62], it appears not to
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be common practice in the health economic modelling of
depression treatments. This is a shortcoming that may
cause flawed decision making.
We identified a larger number of more complex models
in studies published after 2010. Afzali et al. [21] found one
study using ISM, which was conducted in 2006, and no
DES models. After 2010, another study that used ISM and
three studies that used DES models were identified. In
addition, we found three studies that used ‘tunnel’ states to
model time in the CMM (conducted in 2010, 2013 and
2015). This may be an indication of a trend towards more
complex modelling methods to investigate the cost effec-
tiveness of depression treatments. More complex mod-
elling methods may improve the face validity of the
models.
Since depression is a chronic and recurrent disorder, the
history of each patient is crucial for prognosis (e.g. more
previous depressive episodes, more severe depression and
comorbidity are all related to worse prognosis) [40].
Studies that used DES and ISM included patient hetero-
geneity (e.g. age, sex) and tracking of individual history
(e.g. additional depressive episodes during the simulation)
in the model estimations. This may improve not only the
face validity of the models but also the validity of model
predictions.
Nevertheless, we could not judge the validity of model
prediction because it was not reported in the papers. On the
contrary, studies that used DTs and CMM were not
designed to include patient heterogeneity and history.
Therefore, we consider DES and ISM the most appropriate
methods to simulate the course of depression.
In addition, DES may have some advantages over ISM,
such as increased flexibility in time management (no cycles
are used since time runs constantly) and the ability to
model patient interactions (e.g. waiting lists for access to
treatment). However, our search did not detect any study
using the ability of a DES model to simulate patient
interactions. Only empirical comparisons between the dif-
ferent models will allow us to draw firm conclusions on
whether important aspects of depression, such as patient
heterogeneity and time-varying events, can be validly
incorporated in cohort-based models without resulting in
an unwieldy number of health states; this may be easier to
incorporate in microsimulation models.
To our knowledge, such comparisons have not yet been
conducted for depression treatments. One study has com-
pared DES and CMM for HIV treatments [63] and one has
compared them for early breast cancer treatments [64].
Simpson et al. [63] indicated that DES showed better
predictive validity over 5 years. Karnon [64] concluded
that DES represented the data more flexibly than did CMM
but that this advantage was outweighed by the increased
efficiency of CMM (i.e. short computational times, easier
to develop and analyse). Nevertheless, the extent to which
these inferences can be generalized to the evaluation of
depression treatments remains unknown.
In a recent review, Karnon and Afzali [65] presented an
overview of the costs and benefits of using DES to model
healthcare decision problems in general. The authors pro-
posed four factors that decision analysts and researchers
can use to evaluate whether using a DES model would be
beneficial: baseline heterogeneity, disease progression as a
continuous process, time-varying event rates, and prior
events affect subsequent event rates [65]. When consider-
ing depression, it seems that all these factors apply. Ini-
tially, the depressed population is rather heterogeneous.
Furthermore, depressive symptom severity is continuous,
although sometimes it is conventionally modelled as dis-
crete categories (i.e. mild, moderate, severe). In addition,
time is crucial when modelling depression. The longer
patients have depression the less likely they are to expe-
rience remission. Finally, the number of prior depressive
episodes affects the probability of having new episodes.
Thus, a DES model seems to be more suitable for mod-
elling the course of depression than other more simple
methods. However, the results of our review show that
DES modelling is not yet commonly used for depression.
This may limit the validity of the findings of existing
studies.
More guidelines are available to help researchers and
decision makers decide on the most suitable modelling
method to address the problem of interest. The Interna-
tional Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Modeling Good Research Practices task
force provided a thorough description of the advantages
and disadvantages of the available modelling methods in a
series of reports [22, 38, 47]. Finally, the ISPOR Dynamic
Simulation Modeling Emerging Good Practices task force
provided the SIMULATE checklist, which is a tool to assist
modellers decide whether a dynamic modelling method,
such as DES, is necessary or relatively simpler simulation
methods, such as Markov models, are adequate to address
the specific decision problem [66, 67]. In general, these
guidelines are in accordance with our conclusions, indi-
cating that chronic and recurrent health problems require
more complex modelling techniques.
5 Conclusion
The present systematic review described the studies and
compared the modelling techniques that have been used in
the economic evaluation of depression treatments. There
were substantial methodological differences between the
studies, which decreased the comparability of the results.
Since patient heterogeneity and the individual history of
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each patient are important for the prognosis of depression,
DES and ISM simulation methods may be more appro-
priate for a pragmatic representation of the course of
depression. However, direct comparisons between the
available modelling techniques are necessary to yield firm
conclusions.
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